Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

233 - Clinicopathological significance of HER2 and EGFR expression in urothelial carcinoma: a single center study

Date

05 Mar 2018

Session

Poster display

Presenters

Gulrukh Botiralieva

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

G.K. Botiralieva, M. Tillyashaykhov, A. Yusupbekov

Author affiliations

  • National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ
More

Resources

Abstract 233

Urinary bladder cancer is the ninth most common malignancy in the Uzbekistan. 94% cases of urinary bladder cancer made up urothelial carcinoma (UC). There were limited options for patients who are refractory to systemic chemotherapy. Targeted agents as EGFR/HER2 has been proved in a wide range of cancers, but no studies have yet clarified the clinicopathological significance of them in UC. The aim of this study is determination of EGFR/HER2 overexpression which would widen therapeutic options for patients with advanced UC.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings